jwh133  (Tocris)

Journal: Heliyon

Article Title: CB2R activation enhances tumor-associated macrophages-mediated phagocytosis of glioma cell

doi: 10.1016/j.heliyon.2024.e40806

Figure Lengend Snippet: CB2R activation promotes TAMs-mediated phagocytosis of glioma cells. (A) Representative immunofluorescence images of the xenografted brain stained with GFP (green) and CD11b (red) in mice injected with Vehicle, JWH133 or AM630. White arrows indicated the phagocytes. Scale bar: 10 μm. (B) Representative flow cytometry plots depicting the phagocytosis of GFP-labeled glioma cells with CD11b-labeled TAMs in the presence of Vehicle, JWH133, or AM630. (C) The determination of the proportion of phagocytosed GFP cells in mice that received injections of Vehicle, JWH133, or AM630. (D) Quantification of the percentage of GFP and CD11b double-positive cells among all the sorted cells in mice injected with Vehicle, JWH133, or AM630. The format of mean ± SEM is used to display the data. Each group contains n = 6 mice. One-way ANOVA with the Bonferroni correction was used to determine ∗ P < 0.05, ∗∗ P < 0.01 and ∗∗∗∗ P < 0.0001 relative to the control group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: To determine the effect of CB2R manipulation on tumor growth with or without TMZ treatment, mice were treated with vehicle, TMZ (5 mg/kg, i.p., Selleckchem, S1237), AM630 (1.0 mg/kg, Tocris Bioscience, 1120), JWH133 (1.0 mg/kg, Tocris Bioscience, 1343), or the combination of TMZ and JWH133.

Techniques: Activation Assay, Immunofluorescence, Staining, Injection, Flow Cytometry, Labeling, Control

Journal: Heliyon

Article Title: CB2R activation enhances tumor-associated macrophages-mediated phagocytosis of glioma cell

doi: 10.1016/j.heliyon.2024.e40806

Figure Lengend Snippet: CB2R activation promotes TAMs-mediated phagocytosis of glioma cells via increasing the expression of CD36 in TAMs. (A) Representative western blot bands of CD36 and GAPDH from flow cytometry sorted CD11b positive cells in xenografted mice injected with Vehicle, JWH133, or AM630 at day 14 after implantation. (B) Quantification of CD36 and GAPDH from flow cytometry sorted CD11b positive cells with Vehicle, JWH133, or AM630 at day 14 after implantation. (C) Representative immunofluorescence images of xenografted brain tissue depict GFP (green) and CD11b (red) staining in mice injected in each group. White arrows indicated the phagocytes. Scale bar: 10 μm. (D) The determination of the proportion of phagocytosed GFP cells in mice in each group. (E) Representative flow cytometry plots depicting the phagocytosis of GFP-labeled glioma cells with CD11b-labeled TAMs in each group. (F) Quantification of the percentage of GFP and CD11b double-positive cells among all the sorted cells in each group. The format of mean ± SEM is used to display the data. Each group contains n = 6 mice. One-way ANOVA with the Bonferroni correction was used to determine ∗ P < 0.05 and ∗∗∗ P < 0.001 relative to the control group (B). Student t -test was used to determine ∗∗ P < 0.01 relative to the JWH133 group (D and F). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: To determine the effect of CB2R manipulation on tumor growth with or without TMZ treatment, mice were treated with vehicle, TMZ (5 mg/kg, i.p., Selleckchem, S1237), AM630 (1.0 mg/kg, Tocris Bioscience, 1120), JWH133 (1.0 mg/kg, Tocris Bioscience, 1343), or the combination of TMZ and JWH133.

Techniques: Activation Assay, Expressing, Western Blot, Flow Cytometry, Injection, Immunofluorescence, Staining, Labeling, Control

Journal: Heliyon

Article Title: CB2R activation enhances tumor-associated macrophages-mediated phagocytosis of glioma cell

doi: 10.1016/j.heliyon.2024.e40806

Figure Lengend Snippet: JWH133 enhances the therapeutic efficacy of temozolomide (TMZ). (A) Images of the bioluminescence intensity obtained on day 14 post-implantation of representative mice from each treatment group. (B) Tumor progression quantification for each mouse based on flux data obtained using bioluminescence intensity photometry. (C) Kaplan-Meier (K–M) analysis of the survival of each treatment group's mice carrying GL261 xenografts. Each group contains n = 6–10 mice. One-way ANOVA with the Bonferroni correction was used to determine ∗∗∗ P < 0.001 relative to the control group and ## P < 0.01 relative to the TMZ group (B). The K-M method was used for survival analysis, and the log-rank test was used as a comparison (C).

Article Snippet: To determine the effect of CB2R manipulation on tumor growth with or without TMZ treatment, mice were treated with vehicle, TMZ (5 mg/kg, i.p., Selleckchem, S1237), AM630 (1.0 mg/kg, Tocris Bioscience, 1120), JWH133 (1.0 mg/kg, Tocris Bioscience, 1343), or the combination of TMZ and JWH133.

Techniques: Control, Comparison